CXI Subsidiary Decides Gratuitous Transfer for Governance Restructuring, No Impact on Shareholder Value
Zhejiang Zhengsheng Health Technology Group, a subsidiary of CXI, decided to gratuitously transfer its 100% stake in Fujian Yingsheng Huoli Bioengineering to CXI, with a valuation of approximately 313.1 billion KRW.
The transaction aims to simplify governance structure and enhance management efficiency within the same consolidation group, with no cash inflow or outflow.
After completion, Fujian Yingsheng Huoli Bioengineering will become a direct subsidiary of CXI, and no change in existing shareholder equity.
[AI Summary]This is a non-cash restructuring with no dilution or capital change, neutral impact on shareholder value.
KOSDAQ Filing Information
Decision on Disposal of Stocks and Investment Securities in Other Corporations (Major Management Matters of Subsidiary)
Company: CXI Healthcare Technology Group (900120)
Submission: CXI Healthcare Technology Group Limited